This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus
by Zacks Equity Research
Prothena's Q3 loss widened as revenues fell short of estimates, but its Alzheimer and Parkinson's drug programs gained FDA momentum and key collaborations advanced.
RHHBYNegative Net Change BMYNegative Net Change NVONegative Net Change PRTANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
NKTR posts a narrower Q3 loss and a revenue beat, while its rezpeg program advances with key phase IIb milestones.
LLYNegative Net Change NKTRPositive Net Change ANIPPositive Net Change ACADPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble
by Zacks Equity Research
Despite a narrower Q3 loss, NTLA stock plunges after pulling nex-z milestone guidance amid FDA scrutiny in amyloidosis patients.
REGNNegative Net Change ANIPPositive Net Change ACADPositive Net Change NTLANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Company News for Nov 7, 2025
by Zacks Equity Research
Companies In The News Are: CMI, PLNT, PH, AZN.
AZNNegative Net Change PHNegative Net Change CMINegative Net Change PLNTNegative Net Change
auto-tires-trucks consumer-discretionary industrial-products pharmaceuticals
Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans
by Zacks Equity Research
MRNA posts narrower-than-expected Q3 loss and lifts liquidity outlook for 2025, as cost cuts and revised spending plans boost investor sentiment
GSKNegative Net Change PFENegative Net Change MRKNegative Net Change MRNAPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
AZN Q3 Earnings Top Estimates, Sales Rise As Most Key Drugs Outperform
by Zacks Equity Research
AstraZeneca posts strong Q3 results. Core earnings and revenues beat estimates as key drugs like Tagrisso, Imfinzi and Farxiga fuel broad-based growth.
AZNNegative Net Change PFENegative Net Change MRKNegative Net Change
pharmaceuticals
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge.
AZNNegative Net Change COPPositive Net Change RLNegative Net Change MRNAPositive Net Change TRIPPositive Net Change PLNTNegative Net Change TPRPositive Net Change
consumer-discretionary oil-energy pharmaceuticals
Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y
by Zacks Equity Research
CPRX Q3 earnings and revenues beat estimates, driven by strong Firdapse and Agamree sales, while raising the full-year 2025 total revenue guidance.
FOLDNegative Net Change CPRXNegative Net Change ANIPPositive Net Change ACADPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance
by Zacks Equity Research
Viatris tops Q3 earnings and revenue estimates, lifts 2025 outlook, and expands its Japan presence with Aculys Pharma deal.
ALKSNegative Net Change FOLDNegative Net Change CRMDPositive Net Change VTRSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y
by Zacks Equity Research
Recursion Pharmaceuticals narrows its Q3 loss but posts lower-than-expected revenues due to reduced collaboration revenues from its partners.
FOLDNegative Net Change ANIPPositive Net Change ACADPositive Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales
by Zacks Equity Research
ADMA Biologics posts strong Q3 revenues and record Asceniv demand, but shares slip as higher taxes temper net income growth.
ALKSNegative Net Change FOLDNegative Net Change ADMAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Amgen's Q3 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
by Zacks Equity Research
AMGN's Q3 earnings and revenues top estimates as key drugs drive double-digit growth. The company also raises its 2025 outlook.
AZNNegative Net Change NVONegative Net Change LLYNegative Net Change AMGNNegative Net Change
biotechs pharmaceuticals
EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales
by Zacks Equity Research
Exelixis posts strong Q3 results with earnings and revenue beats, boosted by Cabometyx sales, and narrows 2025 guidance.
RHHBYNegative Net Change ALKSNegative Net Change EXELNegative Net Change FOLDNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y
by Zacks Equity Research
RARE's Q3 loss widens and revenues miss estimates, despite year-over-year sales growth of key rare disease drugs.
REGNNegative Net Change BEAMNegative Net Change FOLDNegative Net Change RARENegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up
by Zacks Equity Research
MDGL's wider Q3 loss fails to deter investors, as soaring Rezdiffra sales drive revenues past estimates and lift the stock.
BEAMNegative Net Change FOLDNegative Net Change ANIPPositive Net Change MDGLNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles
by Zacks Equity Research
NVO's Q3 profit and revenues miss expectations as Wegovy and Ozempic growth slows amid U.S. compounding and pricing headwinds.
NVONegative Net Change LLYNegative Net Change BEAMNegative Net Change FOLDNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pharma ETF (IHE) Hit a 52-Week High
by Sanghamitra Saha
IHE just hit a 52-week high. The ETF is up nearly 30% from its low, powered by $LLY's 9.6% past week surge and bold expansion plans. More upside ahead?
LLYNegative Net Change IHENegative Net Change
etfs pharmaceuticals
SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure
by Zacks Equity Research
Sarepta's Q3 loss and the failure of its key DMD study sent shares tumbling, clouding hopes for its PMO therapies and gene therapy Elevidys.
RHHBYNegative Net Change SRPTPositive Net Change ARWRPositive Net Change
biotechs earnings gene-editing gene-therapy medical pharmaceuticals
ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down
by Zacks Equity Research
Zoetis tops Q3 earnings forecasts but misses on revenues and trims 2025 sales outlook, sending shares lower on weak U.S. results.
BEAMNegative Net Change FOLDNegative Net Change ZTSNegative Net Change ANIPPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pfizer Q3 Earnings Beat Estimates, Sales Decline as COVID Demand Cools
by Zacks Equity Research
Pfizer posts Q3 earnings beat and raises EPS guidance, but weaker COVID product sales weigh on overall revenue momentum.
AZNNegative Net Change PFENegative Net Change NVONegative Net Change
pharmaceuticals
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint
by Zacks Equity Research
VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.
VRTXNegative Net Change ANIPPositive Net Change NTLANegative Net Change CRSPNegative Net Change
biotechs pharmaceuticals
Pre-markets Sell Off on No New Economic News
by Mark Vickery
This morning was to bring us new U.S. Trade Deficit figures, Factory Orders and JOLTS, but due to the government shutdown are not out.
BPNegative Net Change ADPNegative Net Change PFENegative Net Change HTZPositive Net Change ADMPositive Net Change SHOPPositive Net Change SPOTPositive Net Change PLTRPositive Net Change
agriculture consumer-discretionary earnings pharmaceuticals
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE reports narrower-than-expected Q3 loss as the biotech advances multiple late-stage studies of azetukalner across epilepsy and mood disorders.
BEAMNegative Net Change NBIXPositive Net Change FOLDNegative Net Change XENENegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline
by Zacks Equity Research
Gilead Sciences' HIV therapies and liver drug Livdelzi drive Q3 revenue growth, offsetting weaker Veklury and Cell Therapy sales.
GSKNegative Net Change ALKSNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Moderna Stock Ahead of Q3 Earnings Report?
by Sundeep Ganoria
MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.
GSKNegative Net Change PFENegative Net Change MRKNegative Net Change MRNAPositive Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines